Regal Partners’s Roivant Sciences ROIV Stock Holding History

Regal Partners’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-100,000	Closed	-$1.17M	–	55
2023 Q3	$1.17M	Buy	+100,000	New	+$1.13M	0.26%	32

Other funds holding ROIV

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Regal Partners's ROIV Position: Q4 2023 in Review

Regal Partners sold out of Roivant Sciences (ROIV) in Q4 2023, closing a stake of 100,000 shares — an estimated $1.17M sold.

Regal Partners first reported a position in ROIV in Q3 2023 and held it in 1 quarter. The position peaked at $1.17M in Q3 2023. 224 funds tracked by Wall St. Rank hold ROIV as of Q4 2023.

Regal Partners reported no remaining Roivant Sciences position as of Q4 2023 after selling out during the quarter.
Regal Partners sold 100,000 Roivant Sciences shares in Q4 2023, an estimated $1.17M.
Regal Partners first reported a position in Roivant Sciences in Q3 2023 and held it in 1 quarter.
Regal Partners's Roivant Sciences position peaked at $1.17M in Q3 2023.
224 funds tracked by Wall St. Rank held Roivant Sciences as of Q4 2023.

Based on Regal Partners's 13F filing for Q4 2023, filed 9 Feb 2024.